Figure 2
From: A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer
Characterization of nanodrug. (A) Transmission electron microscopy (TEM) images of PPA andPPA@aPD-L1(Scale bar = 100 nm). (B) The particle sizes of PP, PPA and PPA@aPD-L1determined by dynamic light scattering (DLS). (C) The zeta potential of PP, PPA and PPA@aPD-L1determined by DLS (n = 3; means ± SD). (D) The particle sizes and polymer dispersity index (PDI) of PPA@aPD-L1 at different times (n = 3; means ± SD) when in the PBS with 10% fetal bovine serum. (E) UV–VIS spectrum of FBZ, PP, PPA and PPA@aPD-L1. (F) The Fourier transform infrared spectroscopy (FTIR) analysis of PP, aPD-L1 and PP@aPD-L1. (G) Critical micelle concentration (CMC) of PPA. (H) The SDS–polyacrylamide gel electrophoresis (PAGE) of free aPD-L1 antibody and PPA@aPD-L1 (lane 1: free aPD-L1, lane 2: PPA@aPD-L1).
